Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Background and hypothesis: Although maintenance treatment with antipsychotics protects against psychotic relapse, high doses may hamper recovery. Therefore, dose reduction or discontinuation may be considered in patients with chronic schizophrenia. Here, we identified risk factors for psychotic relapse when doses are reduced. Study Design: We systematically searched MEDLINE, EMBASE, and PsycINFO from January 1950 through January 2021 and reviewed randomized controlled trials (RCTs) that reported relapse rates after antipsychotic dose reduction or discontinuation in patients with chronic schizophrenia. We calculated relative risks (RRs) with 95% confidence intervals (CIs) per person-year and sought to identify potential risk factors for relapse. The study is registered with PROSPERO (CRD42017058296). Study Results: Forty-seven RCTs (54 patient cohorts, 1746 person-years) were included. The RR for psychotic relapse with dose reduction/discontinuation versus maintenance treatment was 2.3 per person-year (95% CI: 1.9 to 2.8). The RR was higher with antipsychotic discontinuation, dose reduction to less than 3–5 mg haloperidol equivalent (HE), or relatively rapid dose reduction (<10 weeks). The RR was lower with long-acting injectable agents versus oral antipsychotic dose reduction. Other factors that increased the risk of psychotic relapse were younger age and short follow-up time. Conclusions: Clinicians should take several risk factors for psychotic relapse into account when considering dose reduction in patients with chronic schizophrenia. Studies of a relatively fast reduction in antipsychotic dose support a minimum dose of 3–5 mg HE. However, if the dose is tapered more gradually, relapses related to medication withdrawal might be avoided, possibly enabling lower-end doses to be achieved.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931
Tiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Improving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Management of common adverse effects of antipsychotic medications
Stroup, T. S., & Gray, N. (2018) · World Psychiatry · doi:10.1002/wps.20567 · Cited by 572
Wunderink, L., Nieboer, R. M., Wiersma, D., Sytema, S., & Nienhuis, F. J. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.19 · Cited by 567
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
What is the risk‐benefit ratio of long‐term antipsychotic treatment in people with schizophrenia?
Correll, C. U., Rubio, J. M., & Kane, J. M. (2018) · World Psychiatry · doi:10.1002/wps.20516 · Cited by 324
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Antipsychotic maintenance treatment: time to rethink
Moncrieff, J. (2015) · PLoS Medicine · doi:10.1371/journal.pmed.1001861 · Cited by 80
Research works printed but not linked: 89
- Schneider-Thoma, 2022, Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis, Lancet., 399, 824, 10.1016/S0140-6736(21)01997-8 · DOI · Paper page
- Shimomura, 2020, Antipsychotic treatment in the maintenance phase of schizophrenia: an updated systematic review of the guidelines and algorithms, Schizophr Res., 215, 8, 10.1016/j.schres.2019.09.013 · DOI
- Bjornestad, 2020, Antipsychotic treatment—a systematic literature review and meta-analysis of qualitative studies, J Ment Health., 29, 513, 10.1080/09638237.2019.1581352 · DOI
- Yoshida, 2021, Dose-dependent effects of antipsychotics on efficacy and adverse effects in schizophrenia, Behav Brain Res., 402, 113098, 10.1016/j.bbr.2020.113098 · DOI
- Andreasen, 2013, Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study, Am J Psychiatry., 170, 609, 10.1176/appi.ajp.2013.12050674 · DOI · Paper page
- Gallego, 2012, Safety and tolerability of antipsychotic polypharmacy, Expert Opin Drug Saf., 11, 527, 10.1517/14740338.2012.683523 · DOI · Paper page
- Longdon, 2017, “People with problems, not patients with illnesses”: using psychosocial frameworks to reduce the stigma of psychosis, Isr J Psychiatry Relat Sci, 54, 24
- Wang, 2018, Schizophrenia and prospective memory impairments: a review, Clin Neuropsychol., 32, 836, 10.1080/13854046.2017.1406144 · DOI
- Harrow, 2012, Do all schizophrenia patients need antipsychotic treatment continuously throughout their lifetime? A 20-year longitudinal study, Psychol Med., 42, 2145, 10.1017/S0033291712000220 · DOI · Paper page
- Moilanen, 2013, Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication. A 10-year follow-up of the Northern Finland 1966 Birth Cohort Study, Eur Psychiatry., 28, 53, 10.1016/j.eurpsy.2011.06.009 · DOI · Paper page
- Harrow, 2014, Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study, Psychol Med., 44, 3007, 10.1017/S0033291714000610 · DOI · Paper page
- Tandon, 2009, Schizophrenia, “just the facts” 4. Clinical features and conceptualization, Schizophr Res., 110, 1, 10.1016/j.schres.2009.03.005 · DOI · Paper page
- Gaebel, 2014, Are there clinically useful predictors and early warning signs for pending relapse?, Schizophr Res., 152, 469, 10.1016/j.schres.2013.08.003 · DOI
- Taipale, 2022, Real world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study, Lancet Psychiatry., 9, 271, 10.1016/S2215-0366(22)00015-3 · DOI
- Tani, 2020, Factors associated with successful antipsychotics dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials, Neuropsychopharmacology., 45, 887, 10.1038/s41386-019-0573-7 · DOI
- Lally, 2015, Antipsychotic medication in schizophrenia: a review, Br Med Bull., 114, 169, 10.1093/bmb/ldv017 · DOI · Paper page
- Häfner, 2003, Gender differences in schizophrenia, Psychoneuroendocrinology., 28, 17, 10.1016/S0306-4530(02)00125-7 · DOI · Paper page
- Seeman, 2019, Does gender influence outcome in schizophrenia?, Psychiatr Q., 90, 173, 10.1007/s11126-018-9619-y · DOI
- Kasckowa, 2001, Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients, Psychiatr Res., 103, 69, 10.1016/S0165-1781(01)00260-8 · DOI
- Sugai, 2016, Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: a nationwide survey, Schizophr Res., 171, 68, 10.1016/j.schres.2016.01.016 · DOI
- Nasrallah, 2007, The case for long-acting antipsychotic agents in the post-CATIE era, Acta Psychiatr Scand., 115, 260, 10.1111/j.1600-0447.2006.00982.x · DOI · Paper page
- Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ., 339, b2535, 10.1136/bmj.b2535 · DOI · Paper page
- Higgins, 2021, Assessing risk of bias in a randomized trial.
- Borenstein, 2009, Introduction to Meta-Analysis, 10.1002/9780470743386 · DOI · Paper page
- Cook, 2000, Hypothesis testing, Prim Care Respir J., 8, 16, 10.1038/pcrj.2000.6 · DOI
- Leucht, 2021, Examination of dosing of antipsychotic drugs for relapse prevention in patients with stable schizophrenia: a meta-analysis, JAMA Psychiatry., 78, 1238, 10.1001/jamapsychiatry.2021.2130 · DOI · Paper page
- Højlund, 2021, Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials, Lancet Psychiatry., 8, 471, 10.1016/S2215-0366(21)00078-X · DOI
- Higgins, 2002, Quantifying heterogeneity in a meta-analysis, Stat Med., 21, 1539, 10.1002/sim.1186 · DOI · Paper page
- Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ., 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
- Diamond, 1960, Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage, J Nerv Ment Dis., 131, 247, 10.1097/00005053-196009000-00006 · DOI
- Blackburn, 1961, Behavioral effects of interrupting and resuming tranquilizing medication among schizophrenics, J Nerv Ment Dis., 133, 303, 10.1097/00005053-196110000-00005 · doi:10.1097/00005053-196110000-00005
- Freeman, 1962, Prolonged withdrawal of chlorpromazine in chronic patients, Dis Nerv Syst., 23, 522
- Whittaker, 1963, Withdrawal of perphenazine in chronic schizophrenia, Br J Psychiatry., 109, 422, 10.1192/bjp.109.460.422 · DOI · Paper page
- Marjerrison, 1964, Withdrawal of long-term phenothiazines from chronically hospitalized psychiatric patients, Can Psychiatr Assoc J., 9, 290, 10.1177/070674376400900404 · DOI
- Caffey, 1964, Discontinuation or reduction of chemotherapy in chronic schizophrenics, J Chronic Dis., 17, 347, 10.1016/0021-9681(64)90075-X · DOI
- Melnyk, 1966, Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients, Can Psychiatr Assoc J., 11, 410, 10.1177/070674376601100507 · DOI
- Garfield, 1966, Withdrawal of ataractic medication in schizophrenic patients, Dis Nerv Syst., 27, 321
- Morton, 1968, A study of the withdrawal of chlorpromazine or trifluoperazine in chronic schizophrenia, Am J Psychiatry., 124, 1585, 10.1176/ajp.124.11.1585 · DOI
- Rassidakis, 1970, Withdrawal of antipsychotic drugs from chronic psychiatric patients, Bull Menninger Clin., 34, 216
- Baro, 1970, Maintenance therapy of chronic psychotic patients with a weekly oral dose of R 16341. A controlled double-blind study, J Clin Pharmacol., 10, 330
- Hershon, 1972, Persistence of extra-pyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy, Br J Psychiatry., 120, 41, 10.1192/bjp.120.554.41 · DOI
- Ota, 1973, A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia, J Clin Pharmacol., 13, 99
- Andrews, 1976, A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients, Br J Psychiatry., 128, 451, 10.1192/bjp.128.5.451 · DOI
- Lonowski, 1978, Gradual reduction of neuroleptic drugs among chronic schizophrenics. A double-blind controlled study, Acta Psychiatr Scand., 57, 97, 10.1111/j.1600-0447.1978.tb06877.x · DOI
- Levine, 1980, Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study, Adv Biochem Psychopharmacol., 24, 483
- Lehmann, 1980, Drug-response differences of high and standard dosage of fluphenazine-decanoate in relation to schizophrenic symptoms, Pharmakopsychiatr Neuropsychopharmakol., 13, 117, 10.1055/s-2007-1019621 · doi:10.1055/s-2007-1019621
- Cheung, 1981, Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs?, Br J Psychiatry., 138, 490, 10.1192/bjp.138.6.490 · DOI · Paper page
- Odejide, 1982, Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients, J Clin Psychiatry., 43, 195
- Lehmann, 1983, Minimal maintenance medication: effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients, Compr Psychiatry., 24, 293, 10.1016/0010-440X(83)90057-3 · DOI
- Johnson, 1983, The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences, Acta Psychiatr Scand., 67, 339, 10.1111/j.1600-0447.1983.tb00351.x · DOI · Paper page
- Kane, 1983, Low dose medication strategies in the maintenance treatment of schizophrenia, Schizophr Bull., 9, 528, 10.1093/schbul/9.4.528 · DOI
- Wistedt, 1983, Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology, Acta Psychiatr Scand., 67, 378, 10.1111/j.1600-0447.1983.tb09718.x · DOI
- Channabasavanna, 1987, Penfluridol maintenance therapy in schizophrenia: a controlled study, Indian J Psychiatry., 29, 333
- Cookson, 1987, The effects of a 50% reduction of cis(z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime, Int Clin Psychopharmacol., 2, 141, 10.1097/00004850-198704000-00008 · DOI · Paper page
- Johnson, 1987, Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia, Br J Psychiatry., 151, 634, 10.1192/bjp.151.5.634 · DOI · Paper page
- Hogarty, 1988, Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study, Arch Gen Psychiatry., 45, 797, 10.1001/archpsyc.1988.01800330021002 · DOI · Paper page
- Faraone, 1989, Neuroleptic dose reduction in persistently psychotic patients, Hosp Community Psychiatry., 40, 1193
- Sampath, 1992, Neuroleptic discontinuation in the very stable schizophrenic patient: relapse rates and serum neuroleptic levels, Hum Psychopharmacol., 7, 355, 10.1002/hup.470070405 · DOI
- Inderbitzin, 1994, A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients, Am J Psychiatry., 151, 1753, 10.1176/ajp.151.12.1753 · DOI · Paper page
- Hogarty, 1995, Pharmacotherapy of impaired affect in recovering schizophrenic patients, Arch Gen Psychiatry., 52, 29, 10.1001/archpsyc.1995.03950130029004 · DOI · Paper page
- Huttunen, 1996, Low- and standard-dose depot haloperidol combined with targeted oral neuroleptics, Psychiatr Serv., 47, 83, 10.1176/ps.47.1.83 · DOI
- Hirschowitz, 1997, The dose reduction in schizophrenia (DORIS) study: a final report, Schizophr Res., 23, 31, 10.1016/S0920-9964(96)00074-6 · DOI
- Schooler, 1997, Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment, Arch Gen Psychiatry., 54, 453, 10.1001/archpsyc.1997.01830170079011 · DOI · Paper page
- Carpenter, 1999, Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks, Am J Psychiatry., 156, 412, 10.1176/ajp.156.3.412 · DOI · Paper page
- Volavka, 2000, High-dose treatment with haloperidol: the effect of dose reduction, J Clin Psychopharmacol., 20, 252, 10.1097/00004714-200004000-00020 · DOI
- Arato, 2002, A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the ziprasidone extended use in schizophrenia (ZEUS) study, Int Clin Psychopharmacol., 17, 207, 10.1097/00004850-200209000-00001 · DOI · Paper page
- Khazaie, 2005, Comparative efficacy of every 2 weeks versus every 6 weeks injections of fluphenazine decanoate, Arch Iranian Med., 8, 109
- Uchida, 2006, Reducing the dose of antipsychotic agents ameliorates visual hypersensitivity attack. An ideal treatment option in terms of the adverse effect, J Clin Psychopharmacol., 26, 50, 10.1097/01.jcp.0000195384.04008.25 · DOI
- Kramer, 2007, Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomised, double-blind, placebocontrolled study, J Clin Psychopharmacol., 27, 6, 10.1097/JCP.0b013e31802dda4a · DOI · Paper page
- Kane, 2010, Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia, Am J Psychiatry., 167, 181, 10.1176/appi.ajp.2009.07081221 · DOI · Paper page
- Wang, 2010, Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial, Am J Psychiatry., 167, 676, 10.1176/appi.ajp.2009.09030358 · DOI · Paper page
- Takeuchi, 2013, Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study, Schizophr Bull., 39, 993, 10.1093/schbul/sbt090 · DOI · Paper page
- Yamanouchi, 2014, Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose method, Int J Neuropsychopharmacol., 18, pyu016, 10.1093/ijnp/pyu016 · DOI
- Zhou, 2018, Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: a single-blinded, 52-week, randomized controlled study, J Psychopharmacol., 32, 524, 10.1177/0269881118756062 · DOI
- Huhn, 2021, Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial, Eur Arch Psychiatry Clin Neurosci., 271, 293, 10.1007/s00406-020-01109-y · DOI · Paper page
- Tiihonen, 2016, Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow-up study, Am J Psychiatry., 173, 600, 10.1176/appi.ajp.2015.15050618 · DOI · Paper page
- De Hert, 2015, The use of continuous treatment versus placebo or intermittent treatment strategies in stabilized patients with schizophrenia: a systematic review and meta-analysis of randomized controlled trials with first- and second-generation antipsychotics, CNS Drugs., 29, 637, 10.1007/s40263-015-0269-4 · DOI
- Ostuzzi, 2022, Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis, Lancet Psychiatry., 9, 614, 10.1016/S2215-0366(22)00158-4 · DOI
- Horowitz, 2022, Confounding of antipsychotic discontinuation studies by withdrawal-related relapse, Schizophr Bull., 48, 294, 10.1093/schbul/sbab146 · DOI
- Brandt, 2022, Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis, Lancet Psychiatry., 9, 232, 10.1016/S2215-0366(22)00014-1 · DOI
- Horowitz, 2021, Tapering antipsychotic medication: practical considerations, Psychol Med.
- Leucht, 2021, Comment & Response to Højlund and colleagues, JAMA Psychiatry., 177, e1
- Weiden, 2017, Does half-life matter after antipsychotic discontinuation?, J Clin Psychiatry., 78, e813, 10.4088/JCP.16m11308 · DOI · Paper page
- Matuskey, 2016, Age-related changes in binding of the D2/3 receptor radioligand [11C](+)PHNO in healthy volunteers, Neuroimage., 130, 241, 10.1016/j.neuroimage.2016.02.002 · DOI
- Seamen, 2019, Differential regional decline in dopamine receptor availability across adulthood: linear and nonlinear effects of age, Hum Brain Mapp., 40, 3125, 10.1002/hbm.24585 · DOI · Paper page
- Johnstone, 1994, How high is the relapse rate in schizophrenia?, Acta Psychiatr Scand Suppl., 382, 6, 10.1111/j.1600-0447.1994.tb05858.x · DOI
- Moncrieff, 2019, Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction), BMJ Open., 9, e030912, 10.1136/bmjopen-2019-030912 · DOI
- Horowitz, 2022, Limitations in research on maintenance treatment for individuals with schizophrenia, JAMA Psychiatry., 79, 83, 10.1001/jamapsychiatry.2021.3400 · DOI
- Moncrieff, 2020, Definitions of relapse in trials comparing antipsychotic maintenance with discontinuation or reduction for schizophrenia spectrum disorders: a systematic review, Schizophr Res., 225, 47, 10.1016/j.schres.2019.08.035 · DOI
Cited by
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198463 · Cited by 12
O’Neill, J. R., Taylor, D. M., & Horowitz, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241272790 · Cited by 7
Metadata
- Authors
- Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-10-06
- Volume
- 49
- Issue
- 1
- Pages
- 11-23
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W4302304702
- Cited by
- 58
- References
- 14
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1093/schbul/sbac138
- The paper
- Bogers, J. P. A. M., Hambarian, G., Walburgh Schmidt, N., Vermeulen, J. M., & de Haan, L. (2023). Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbac138
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.